GlaxoSmithKline PLC's blockbuster asthma treatment Advair Diskus (fluticasone/salmeterol) will have more time on the market alone now that a near-term headwind has been removed. Mylan NV was expecting US FDA action on its ANDA for a generic version of Advair by June 27, but the agency notified the company that it should expect a complete response letter rather than approval.
Mylan told investors after market close June 13 that it expects to receive a CRL from FDA on the June...







